

\*\*\*\*\*  
 \*\*\* TX REPORT \*\*\*  
 \*\*\*\*\*



TRANSMISSION OK

TX/RX NO 1750  
 CONNECTION TEL 30727#0027#17038729305p#  
 CONNECTION ID  
 ST. TIME 01/22 19:01  
 USAGE T 02'47  
 PGS. SENT 10  
 RESULT OK

**FACSIMILE TRANSMISSION**

Transmission problems: 858.720.2630

**Brobeck**

ATTORNEYS AT LAW

**January 22, 2002**

Brobeck, Phleger & Harrison LLP  
 12390 El Camino Real  
 San Diego, California 92130-2081  
 PHONE 858.720.2500  
 FAX 858.720.2555  
 www.brobeck.com

PAGES TO FOLLOW COVER	9	USER ID	006656	CMID NUMBER	030727.0027.CON1
-----------------------	---	---------	--------	-------------	------------------

TO			
RECIPIENT	COMPANY	TELEPHONE	FAX
TC1600 - Customer Service (1619)	United States Patent and Trademark Office	800.786.9199	703.872.9305

FROM			
SENDER	EMAIL	TELEPHONE	FAX
Jeff Beno	Jbeno@Brobeck.com	(858) 720-2630	(858) 720-2555

**MESSAGE**

RE: U.S. Patent Application Serial No.: 09/978,454  
 Filing Date: October 15, 2001

**FACSIMILE TRANSMISSION**

Transmission problems: 858.720.2630

**Brobeck**

ATTORNEYS AT LAW

**January 22, 2002**

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, California 92130-2081  
PHONE 858.720.2500  
FAX 858.720.2555  
www.brobeck.com

PAGES TO FOLLOW COVER	9	USER ID	006656	CMID NUMBER	030727.0027.CON1
-----------------------	---	---------	--------	-------------	------------------

**TO**

RECIPIENT	COMPANY	TELEPHONE	FAX
TC1600 – Customer Service (1619)	United States Patent and Trademark Office	800.786.9199	703.872.9305

**FROM**

SENDER	EMAIL	TELEPHONE	FAX
Jeff Beno	Jbeno@Brobeck.com	(858) 720-2630	(858) 720-2555

**MESSAGE**

RE: U.S. Patent Application Serial No.: 09/978,454  
Filing Date: October 15, 2001

**P R I V I L E G E D   A N D   C O N F I D E N T I A L**

All information transmitted hereby is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and mail the original message to us at the above address.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Mark D. Erion, et al.

Serial No.: 09/978,454

Filed: October 15, 2001

For: NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS

)  
) Group Art Unit: 1619

)  
) Examiner: To be assigned

TRANSMITTAL LETTER

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed are the following documents:


- First Preliminary Amendment; and
- Associate Power of Attorney.

CERTIFICATE OF TRANSMISSION  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

JANUARY 22, 2002  
Date of Transmission

JEFF BEVO  
Name of Person Transmitting Paper

  
Signature of Person Transmitting Paper

No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required or to credit any overpayment to our Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 1/22/02

By: Jessica R. Wolff  
Jessica R. Wolff  
Reg. No. 37,261

JRW:jxb

**BROBECK, PHLEGER & HARRISON LLP**  
12390 El Camino Real  
San Diego, CA 92130-2081  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Mark D. Erion, et al.

Serial No.: 09/978,454

Filed: October 15, 2001

For: NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS

)  
) Group Art Unit: 1619

)  
) Examiner: To be assigned

ASSOCIATE POWER OF ATTORNEY

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The undersigned attorney in this application hereby appoints Cynthia H. O'Donohue, Registration No. 44,980, of Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, Telephone (858) 587-2770, to transact all business in the Patent and

CERTIFICATE OF TRANSMISSION  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

JANUARY 22, 2002  
Date of Transmission

JEFF BENO  
Name of Person Transmitting Paper


[Signature]  
Signature of Person Transmitting Paper

Trademark Office in connection with the above-identified application.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated: 1/22/02

By:   
Jessica R. Wolff  
Reg. No. 37,261

JRW:jxb

**BROBECK, PHLEGER & HARRISON LLP**

12390 El Camino Real

San Diego, CA 92130-2081

Telephone: (858) 720-2500

Facsimile: (858) 720-2555

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Erion et al.

Serial No.: 09/978,454

Filed: October 15, 2001

Title: NOVEL PRODRUGS FOR  
PHOSPHORUS-CONTAINING  
COMPOUNDS

Group Art Unit: 1619

Examiner: To Be Assigned

Commissioner for Patents  
Washington, D.C. 20231

**FIRST PRELIMINARY AMENDMENT**

Dear Sir:

Prior to examination of the subject application, Applicants request that the Examiner enter the following amendments. It is believed that no additional fee is due for filing this amendment. If, however, any fee should become due or credit become payable during the pendency of these proceedings, the Examiner is authorized to charge or credit the same to deposit account number 50-1273.

**AMENDMENTS**

In the Claims

Please cancel claim 1.

Please add new claims as follows:

--2. (New) A pharmaceutical composition comprising a compound of Formula I:


**CERTIFICATE OF TRANSMISSION**  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

JANUARY 22, 2002  
Date of Transmission

JEFF BEND  
Name of Person Transmitting Paper

  
Signature of Person Transmitting Paper



Formula I

wherein:

V, W and W' are independently selected from the group consisting of hydrogen, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, and 1-alkynyl; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein the cyclic group optionally contains one heteroatom and is substituted with a hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy group attached to a carbon atom that is three atoms away from both oxygen atoms that are attached to the phosphorus atom; or

together V and Z are connected via an additional 3-5 atoms to form a cyclic group wherein the cyclic group optionally contains one heteroatom, and is fused to an aryl group, at the beta and gamma position to the oxygen attached to the phosphorus; or

together V and W are connected via an additional three carbon atoms to form an optionally substituted cyclic group containing six carbon atoms and is optionally substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy groups, wherein such substituent is attached to one of said carbon atoms that is three atoms away from an oxygen attached to the phosphorus atom; or

together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

together W and W' are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; or

Z is selected from  $-\text{CHR}^2\text{OH}$ ,  $-\text{CHR}^2\text{OC}(\text{O})\text{R}^3$ ,  $-\text{CHR}^2\text{OC}(\text{S})\text{R}^3$ ,  $-\text{CHR}^2\text{OC}(\text{S})\text{OR}^3$ ,  $-\text{CHR}^2\text{OC}(\text{O})\text{SR}^3$ ,  $-\text{CHR}^2\text{OCO}_2\text{R}^3$ ,  $-\text{OR}^2$ ,  $-\text{SR}^2$ ,  $-\text{CHR}^2\text{N}_3$ ,  $-\text{CH}_2(\text{aryl})$ ,  $-\text{CH}(\text{aryl})\text{OH}$ ,  $-\text{CH}(\text{CH}=\text{CR}^2)\text{OH}$ ,  $-\text{CH}(\text{C}\equiv\text{CR}^2)\text{OH}$ ,  $-\text{R}^2$ ,  $-\text{NR}^2_2$ ,  $-\text{OC}(\text{O})\text{R}^3$ ,  $-\text{OCO}_2\text{R}^3$ ,  $-\text{SC}(\text{O})\text{R}^3$ ,  $-\text{SCO}_2\text{R}^3$ ,



$-\text{NHC(O)R}^2$ ,  $-\text{NHCO}_2\text{R}^3$ ,  $-\text{CH}_2\text{NH(aryl)}$ ,  $-(\text{CH}_2)_p\text{OR}^{12}$ , and  $-(\text{CH}_2)_p\text{SR}^{12}$ ;

$\text{R}^2$  is selected from the group consisting of  $\text{R}^3$  and hydrogen;

$\text{R}^3$  is selected from the group consisting of alkyl, aryl, alicyclic, and aralkyl;

$\text{R}^{12}$  is selected from the group consisting of hydrogen, and lower acyl; and

$p$  is an interger 2 or 3;

with the provisos that:

a)  $\text{V}$ ,  $\text{Z}$ ,  $\text{W}$ , and  $\text{W}'$  are not all hydrogen; and

b) when  $\text{Z}$  is  $-\text{R}^2$ , then at least one of  $\text{V}$ ,  $\text{W}$ , and  $\text{W}'$  is not hydrogen, alkyl, aralkyl, or alicyclic; and

$\text{M}$  is selected from the group that, attached to  $\text{PO}_3^{2-}$ ,  $\text{P}_2\text{O}_6^{3-}$ , or  $\text{P}_3\text{O}_9^{4-}$ , is biologically active *in vivo* and that is attached to the phosphorus atom in Formula I via a carbon, oxygen, or nitrogen atom, with the proviso that  $\text{M-PO}_3^{2-}$  is not an FBPase inhibitor;

wherein said compound of Formula I is converted to  $\text{MPO}_3\text{H}_2$  by human liver microsomes;

pharmaceutically acceptable salts of Formula I;

and a pharmaceutically acceptable excipient.

3. (New) The pharmaceutical composition of claim 2, wherein  $\text{MH}$  is 9-(2-phosphonylmethoxyethyl)adenine (PMEA) or analogues thereof.

4. (New) The pharmaceutical composition of claim 2, wherein  $\text{MH}$  is 9-(2-phosphonylmethoxyethyl)adenine (PMEA).

5. (New) The pharmaceutical composition of claim 2, wherein  $\text{MH}$  is selected from penciclovir, 3TC, ACV, PMPA, araC, ribavirin, and 5-fluoro-2'-deoxyuridine.

6. (New) The pharmaceutical composition of claim 2, wherein  $\text{MH}$  is radiolabelled 2'-deoxy-5-Iodouridine.

7. (New) The pharmaceutical composition of claim 6 wherein  $\text{MH}$  is 2'-deoxy-5- $^{131}\text{I}$ -iodouridine.

8. (New) The pharmaceutical composition of claim 2, wherein V is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl.
9. (New) The pharmaceutical composition of claim 2, wherein the prodrug is in the *cis* configuration.
10. (New) The pharmaceutical composition of claim 8, wherein the prodrug is in the *cis* configuration.
11. (New) The pharmaceutical composition of Claim 5, wherein MH is araC and V is a heteroaryl group.
12. (New) The pharmaceutical composition of claim 11, wherein V is 4-pyridyl.--

**REMARKS**

Claim 1 is pending. Upon entry of this First Preliminary Amendment, claims 2-12 will be pending. Support for these new claims can be found throughout the originally filed specification. For example, support can be found where noted in the following table:

Claim	Support
2	Originally Filed Claim 95; Page 128, line 17, to page 132, line 10
3	Pages 38-39
4	Originally Filed Claim 98; page 39
5	Page 37, line 30, to page 38, line 14
6	Page 39, line 22; page 42, lines 19-23
7	Page 42, lines 19-23
8	Originally Filed Claim 95
9	Page 57, lines 18-20
10	Page 57, lines 18-20
11	Page 68, lines 20-23
12	Page 68, lines 20-23

Respectfully Submitted,

Erion et al.

Date: 1/22/02

By: Jessica R. Wolff

Jessica R. Wolff  
Reg. No. 37,261

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, CA 92130-2081  
Direct Dial: (858)720-2696  
Facsimile: (858)720-2555